MediciNova (NASDAQ:MNOV – Get Free Report) and Harrow (NASDAQ:HROW – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.
Volatility & Risk
MediciNova has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Comparatively, Harrow has a beta of 0.24, meaning that its stock price is 76% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and recommmendations for MediciNova and Harrow, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MediciNova | 1 | 1 | 4 | 1 | 2.71 |
| Harrow | 1 | 2 | 8 | 0 | 2.64 |
Institutional & Insider Ownership
9.9% of MediciNova shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 14.0% of MediciNova shares are owned by company insiders. Comparatively, 12.8% of Harrow shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares MediciNova and Harrow”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MediciNova | $410,000.00 | 309.73 | -$12.00 million | ($0.21) | -12.29 |
| Harrow | $272.30 million | 4.55 | -$5.14 million | ($1.00) | -33.07 |
Harrow has higher revenue and earnings than MediciNova. Harrow is trading at a lower price-to-earnings ratio than MediciNova, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares MediciNova and Harrow’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MediciNova | -1,168.70% | -26.51% | -24.39% |
| Harrow | -13.51% | -38.00% | -3.37% |
Summary
MediciNova beats Harrow on 9 of the 15 factors compared between the two stocks.
About MediciNova
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
About Harrow
Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.
